You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Saccharomyces cerevisiae

Showing 1 - 25 of 120
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Irritable Bowel Syndrome Trial in Karachi (Saccharomyces cerevisiae)

Completed
  • Irritable Bowel Syndrome
  • Saccharomyces cerevisiae
  • Karachi, Sindh, Pakistan
    Dr. Ziauddin University Hospital Clifton
Nov 24, 2021

Nutrition, Healthy Trial in Medellín (Yeast ß-glucan fiber, Placebo)

Active, not recruiting
  • Nutrition, Healthy
  • Yeast β-glucan fiber
  • Placebo
  • Medellín, Antioquia, Colombia
    Program for Research and Control in Tropical Diseases - PECET
Jun 4, 2022

Human Papillomavirus Infection Trial in Guangzhou, Nanjing, Taiyuan (Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58)

Active, not recruiting
  • Human Papillomavirus Infection
  • Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
  • Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
  • Guangzhou, Guangdong, China
  • +2 more
Dec 30, 2022

Human Papilloma Virus Infection Trial in Nanjing (Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus

Completed
  • Human Papilloma Virus Infection
  • Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
  • Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
  • Nanjing, Jiangsu, China
    CDC, Jiangsu Province
Jan 12, 2023

Prostate Cancer, Breast Cancer, Lung Cancer Trial run by the NCI (GI-6207 [Recombinant Saccharomyces Cerevisia, (Yeast CEA

Completed
  • Prostate Cancer
  • +4 more
  • GI-6207 [Recombinant Saccharomyces Cerevisia
  • (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 11, 2019

Immunity, Vaccine Reaction, Influenza Trial in Barcelona (ABBC1 Immunoessential, Placebo)

Completed
  • Immunity
  • +5 more
  • ABBC1 Immunoessential
  • Placebo
  • Barcelona, Spain
    Hospital Mare de Déu de la Mercè - Germanes Hospitalàries
Jul 19, 2022

Medullary Thyroid Cancer (MTC) Trial run by the (GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)])

Unknown status
  • Medullary Thyroid Cancer (MTC)
  • GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
  • Bethesda, Maryland
    NIH Clinical Center
Oct 22, 2019

Constipation-predominant Irritable Bowel Syndrome Trial in France (Saccharomyces cerevisiae CNCM I-3856, Placebo)

Completed
  • Constipation-predominant Irritable Bowel Syndrome
  • Saccharomyces cerevisiae CNCM I-3856
  • Placebo
  • France, France
  • +4 more
May 20, 2019

Vaginal Health Trial in Saint-Herblain (Saccharomyces cerevisiae, dose 500, Saccharomyces cerevisiae, dose 1000, Placebo)

Completed
  • Vaginal Health
  • Saccharomyces cerevisiae, dose 500
  • +2 more
  • Saint-Herblain, France
    Biofortis Mérieux Nutriscience
May 20, 2019

Upper Respiratory Tract Infections, Mental Stress Trial in Park City (Treatment, Placebo)

Recruiting
  • Upper Respiratory Tract Infections
  • Mental Stress
  • Treatment
  • Placebo
  • Park City, Utah
    US Ski and Snowboard Center of Excellence
Jun 14, 2023

Triple Negative Breast Cancer Trial in El Segundo (drug, biological, procedure)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Aldoxorubicin HCl
  • +17 more
  • El Segundo, California
    Chan Soon-Shiong Institute for Medicine
Mar 28, 2022

Schizophrenia, Schizoaffective Disorder Trial in Baltimore (Synbiotic Supplement, Inert Compound)

Enrolling by invitation
  • Schizophrenia
  • Schizoaffective Disorder
  • Synbiotic Supplement
  • Inert Compound
  • Baltimore, Maryland
    Sheppard Pratt Health System
Mar 14, 2022

Human Papilloma Virus, Anogenital Wart Trial in Zagazig (the Quadrivalent Vaccine (Gardasil))

Recruiting
  • Human Papilloma Virus
  • Anogenital Wart
  • the Quadrivalent Vaccine (Gardasil)
  • Zagazig, Egypt
    Rana Ehab
Feb 26, 2023

Metabolic Syndrome, Cardiovascular Risk Factor Trial in Athens (Probiotic mix, Placebo)

Withdrawn
  • Metabolic Syndrome
  • Cardiovascular Risk Factor
  • Probiotic mix
  • Placebo
  • Athens, Greece
    Attikon University General Hospital
Mar 30, 2022

IBD, Crohn Disease, Crohn Colitis Trial in Boston (Personalized Risk Estimation for Crohn's Disease (PRE-CD) tool, Standard

Not yet recruiting
  • Inflammatory Bowel Diseases
  • +7 more
  • Personalized Risk Estimation for Crohn's Disease (PRE-CD) tool
  • Standard Crohn's Disease Education
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 11, 2022

ICU Delirium Trial (Beer)

Recruiting
  • ICU Delirium
  • Beer
  • Water
  • Basel, Switzerland
    University Hospital Basel
Jan 31, 2023

Chronic Hepatitis B Trial in Zhengzhou (PegIFN a- 2b)

Completed
  • Chronic Hepatitis B
  • PegIFN α- 2b
  • Zhengzhou, Henan, China
    Henan Provincial People's Hospital
Jul 11, 2022

Metastatic Pancreatic Adenocarcinoma Trial (odetiglucan, CDX-1140)

Not yet recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • odetiglucan
  • CDX-1140
  • (no location specified)
Jul 29, 2022

Bipolar Depression Trial in Towson (Probiotic Supplement, Inert Compound)

Enrolling by invitation
  • Bipolar Depression
  • Probiotic Supplement
  • Inert Compound
  • Towson, Maryland
    Sheppart Pratt Health System
Mar 14, 2022

Triple Negative Breast Cancer (TNBC) Trial in El Segundo (Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl)

Withdrawn
  • Triple Negative Breast Cancer (TNBC)
  • El Segundo, California
    Chan Soon-Shiong Institute for Medicine
Mar 28, 2022

Crohn's Disease, IBD Trial in Montréal (Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally., Itraconazole's

Recruiting
  • Crohn's Disease
  • Inflammatory Bowel Diseases
  • Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.
  • Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.
  • Montréal, Quebec, Canada
  • +2 more
Apr 20, 2022

Schizophrenia, Schizoaffective Disorder Trial in Towson (Sulforaphane Nutraceutical, Identical-appearing Placebo)

Completed
Has Results
  • Schizophrenia
  • Schizoaffective Disorder
  • Sulforaphane Nutraceutical
  • Identical-appearing Placebo
  • Towson, Maryland
    Sheppart Pratt Health System
Jul 7, 2021

Candidiasis, Vulvovaginal Trial in Villeurbanne (Saccharomyces cerevisiae, Placebo)

Terminated
  • Candidiasis, Vulvovaginal
  • Saccharomyces cerevisiae
  • Placebo
  • Villeurbanne, France
    Dermscan
Jun 11, 2018

Crohn Disease, Genetic Predisposition, IBD Trial in Roanoke (Capsule endoscopy)

Terminated
  • Crohn Disease
  • +2 more
  • Capsule endoscopy
  • Roanoke, Virginia
    Carilion Clinic
Dec 9, 2022

Dyslipidemias Trial in Lille (Saccharomyces cerevisiae, Lynside Wall Basic, Placebo)

Completed
  • Dyslipidemias
  • Saccharomyces cerevisiae
  • +2 more
  • Lille, France
    Institut Pasteur de Lille
Jun 11, 2018